Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.
Spectrum Equity reduces, but still retains a significant position in GoodRx Holdings, Inc. (NASDAQ: GDRX) according to Amendment No. 6 to its Schedule 13D. The filing reflects events through 2 July 2025 and amends the original Schedule 13D first filed in June 2021 and most recently updated in June 2025.
Key ownership data: the five affiliated reporting entities — Spectrum Equity VII, L.P.; Spectrum Equity Associates VII, L.P.; Spectrum VII Investment Managers’ Fund, L.P.; Spectrum VII Co-Investment Fund, L.P.; and SEA VII Management, LLC — now beneficially own an aggregate 14,905,133 Class A shares, equal to 12.9 % of the outstanding Class A common stock (115,205,298 shares assumed outstanding). The bulk of the holding (14,865,346 shares) resides in Spectrum Equity VII, L.P., with two smaller funds owning 25,445 and 14,342 shares, respectively.
Recent transactions:
- Pro-rata distribution: On 2 July 2025, Spectrum Equity VII, L.P. distributed 3,989,323 Class A shares of GoodRx to its limited partners for no consideration (the “July 2025 Distribution”).
- Follow-on sales: After the distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers’ Fund, L.P. sold a combined 10,677 Class A shares in the open market, generating net proceeds of $50,606.46.
Control structure: SEA VII Management, LLC is the general partner of the other Spectrum vehicles and, together with eight named individuals, shares voting and dispositive power over the reported shares. Each individual disclaims beneficial ownership.
Implications for investors: The 3.99 million-share distribution lowers Spectrum Equity’s direct stake while increasing GoodRx’s public float, potentially improving liquidity but signalling a partial exit by an early sponsor. Despite the reduction, Spectrum Equity remains a >10 % beneficial owner, so it continues to be a significant shareholder with aligned interests, although further sell-downs remain possible. No other material changes, litigation matters or additional share transactions were reported in the past 60 days.